New White Paper Reviews the Affordable Care Act Before Its Upcoming Repeal

Share Article

New white paper by Alliance Life Sciences, authored by Robert Blank, looks into how pharmaceutical manufacturers are dealing with the changes brought on by the ACA that were particularly substantial within their pricing, contracting, and revenue management divisions. Understanding these factors is critical to enable companies to better prepare for and respond to any forthcoming legislation, which appears to be rapidly approaching.

Alliance Life Sciences Consulting Group releases White Paper, authored by Robert Blank. For pharmaceutical manufacturers, the changes brought on by the ACA were particularly substantial within their pricing, contracting, and revenue management divisions. Understanding these factors is critical to enable companies to better prepare for and respond to any forthcoming legislation, which appears to be rapidly approaching.

The white paper, “The Affordable Care Act: A Review Before Repeal” provides insight into:

  • The Medicaid eligibility expansion and a brief history of changes to the Medicaid Drug Rebate Program (MDRP) since its inception in OBRA-90
  • The 340B Drug Pricing Program expansion
  • How changes have affected the administration of contracts and transactions for Managed Care, Medicaid, Chargebacks, and the Medicare Part D Coverage Gap
  • Next steps and considerations for pharmaceutical manufacturers if the ACA is repealed

Download a complimentary copy of the white paper, “The Affordable Care Act: A Review Before Repeal” - https://tinyurl.com/j5j9mx5

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sophie Ferronato
Alliance Life Sciences
since: 07/2010
Like >
Visit website